Evidence map›Paper›PMID 39699412›Full record

ReviewEinstein (Sao Paulo, Brazil)2024

Efficacy of treatment with tumor-infiltrating lymphocytes as adoptive cell therapy: an integrative review.

Lucas Marques Soares da Silva, Eleni Solange de Brito Gomes, Julia Hailer Vieira, Murilo Porfírio de Aguiar, Saulo Fernando Moreira da Silva, Marcia Antoniazi Michelin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Einstein (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lucas Marques Soares da SilvaInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0000-0001-5512-3866
Eleni Solange de Brito GomesInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0009-0000-5816-2457
Julia Hailer VieiraInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0009-0005-4103-8771
Murilo Porfírio de AguiarInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0000-0002-7533-0763
Saulo Fernando Moreira da SilvaInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0000-0001-7704-8115
Marcia Antoniazi MichelinInstituto de Pesquisa em Oncologia, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil.ORCID http://orcid.org/0000-0003-0842-8805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis integrative review article examines the efficacy of adoptive cell therapy using tumor-infiltrating lymphocytes, with a particular focus on the treatment of melanomas and other solid tumors.

methodsThe methodology encompasses theme definition, comprehensive database searches, and a critical review of pertinent literature. Of the 1,947 articles initially identified, 15 were meticulously selected based on stringent inclusion and exclusion criteria.

resultsThe findings suggest that tumor-infiltrating lymphocytes-based therapy is particularly effective in treating metastatic melanomas, as noted by its tailored approach and substantial potential. However, the applicability of these findings to other solid tumor types remains limited.

conclusionThis review indicates that adoptive cell therapy using tumor-infiltrating lymphocytes demonstrates efficacy, especially in the treatment of metastatic melanoma, and shows considerable promise for treating solid tumors.

Indexed as

Immunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMelanomaHumansNeoplasmsTreatment Outcome

Identifiers

PMID39699412
PMCPMC11634345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.